In what care setting do doctors see patients with rare diseases? How do they keep up with treatment advances? Can pharmaceutical companies support rare disease treaters and the patient community?
Those were just some of the questions addressed by exclusive research carried out by Cambridge, Massachusetts-based healthcare market research company MedPanel for the current issue of pharmaphorum’s Deep Dive magazine.
The cohort of 100 doctors that took part in the online research are among those at the frontline of treating patients with rare diseases. On average 75% of their professional time is spent on patient care.
The survey focused on five rare diseases: multiple myeloma, lupus, hemophilia, spinal muscular atrophy (SMA) and cystic fibrosis patients (CF). The doctors within the survey that see these patients specialize in rheumatology (25% of respondents), hematology (22%), neurology (18%) and oncology (17%).
Is pharma ready to work more closely with the rare disease community? As Rare Disease Day brings the community together, we’re off to a great start.